Atezolizumab in urothelial bladder carcinoma. (February 2018)

• Record Type: Journal Article
• Authors: Hamilou, Zineb; Lavaud, Pernelle; Loriot, Yohann
• Is Part Of: Future oncology. Volume 14:Number 4(2018)
• Page Start: 331
• Page End: 341
• Publication Date: 2018-02
• Subjects: atezolizumab -- bladder cancer -- immunotherapy -- urothelial carcinoma; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0433
• Languages: English
• ISSNs: 1479-6694

Abstract

Metastatic bladder cancer is an aggressive malignancy with a poor prognosis when presenting with advanced stage. Cisplatin-based therapy has been the mainstay of first-line treatment but therapy in second-line setting has been an unmet medical need for decades. Moreover, many patients are unable to receive cisplatin-based therapy. Recently, immune-checkpoint inhibitors transformed the management and prognosis of many malignancies and will certainly redefine the standard of care for bladder cancer. Atezolizumab, an anti-PD-L1 antibody, was the first immune-checkpoint inhibitor to be approved by the US FDA in May 2016 for patients with urothelial carcinoma. In this review, we discuss the evidence behind this promising drug.